| Title: |
Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001 |
| Authors: |
Ranke, MB; Partsch, CJ; Lindberg, A; Dorr, HG; Bettendorf, M; Hauffa, BP; Schwarz, HP; Mehls, O; Sander, S; Stahnke, N; Steinkamp, H; Said, E; Sippell, W |
| Source: |
European Journal of Endocrinology ; page 625-633 ; ISSN 0804-4643 1479-683X |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2002 |
| Description: |
OBJECTIVES: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Ullrich-Turner syndrome (UTS) based on modalities conceived in the 1980s. DESIGN: Out of 347 near-adult (>16 Years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, X=59%; bone age >15 Years) were available for further anthropometric measurements. RESULTS: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (-1.3/+13) cm above the projected adult height was recorded. Variables were recorded at GH start, after 1 Year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 Years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (DeltaHT) after GH discontinuation was 1.5 cm. Total DeltaHT correlated (P |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| DOI: |
10.1530/eje.0.1470625 |
| Availability: |
https://doi.org/10.1530/eje.0.1470625; https://eje.bioscientifica.com/view/journals/eje/147/5/625.xml |
| Accession Number: |
edsbas.91CA2502 |
| Database: |
BASE |